Dr. Slingluff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Dept of Surgery, University of Virginia PO Box 800709
Charlottesville, VA 22908Phone+1 434-924-9311- Is this information wrong?
Education & Training
- Duke University HospitalResidency, Surgery, 1984 - 1991
- University of Virginia School of MedicineClass of 1984
Certifications & Licensure
- VA State Medical License 1991 - 2024
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1998 Apr 01
- Vaccine Therapy in Treating Patients With Metastatic Melanoma Start of enrollment: 1996 Feb 01
- Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Start of enrollment: 2005 May 09
- Join now to see all
Publications & Presentations
PubMed
- PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.Ali, L., Lenehan, P., Cardot-Ruffino, V., Dias Costa, A., Katz, M., Bauer, T., Nowak, J., Wolpin, B., Abrams, T., Patel, A., Clancy, T., Wang, J., Mancias, J., Reilley...> ;Clinical Cancer Research. 2024 Feb 1
- 2 citationsMulticenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectabl...Matthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin, Chee-Chee Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Andressa Dias Cos...> ;Journal for Immunotherapy of Cancer. 2023 Dec 1
- Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.John F Thompson, John Hyngstrom, Corrado Caracò, Jonathan S Zager, Tiina Jahkola, Tawnya L Bowles, Elisabetta Pennacchioli, Harald J Hoekstra, Marc Moncrieff, Christia...> ;Annals of Surgical Oncology. 2023 Jul 1
- Join now to see all
Press Mentions
- UVA Health Launches World's 1st Ultrasound Immunotherapy Cancer CenterMay 11th, 2022
- World’s First Focused Ultrasound Cancer Immunotherapy Center Will Be at UVAMay 11th, 2022
- Q&A: Cancer Death Rates Are Falling Nationally. Here’s What’s Happening at UVAJanuary 10th, 2020
- Join now to see all
Grant Support
- Postdoctoral Training Grant For MDS In Surgical Oncology ResearchNational Cancer Institute2011
- Melanoma Vaccines Using Mhc-Associated PeptidesNational Cancer Institute2002–2011
- Phase 2: CCI-779 In Combination With Bevacizumab In Stage III Or IV MelanomaNational Center For Research Resources2010
- Intratumoral Interferon Gamma During Vaccination In Metastatic MelanomaNational Center For Research Resources2010
- A Multipeptide Vaccine In Melanoma Patients With Evaluation Of Injection SiteNational Center For Research Resources2009–2010
- Clinical Trial: A Phase II Trial Of Vaccination With Peptides For Patients WithNational Center For Research Resources2008–2010
- Tissue Procurement FacilityNational Cancer Institute2006–2010
- Multi-Peptide Vaccine Administered With Cyclophosphamide For High-Risk MelanomaNational Cancer Institute2006–2010
- Clinical Trial: Evaluation Of Cyclophosphamide With Peptide Vaccines In ParticipNational Center For Research Resources2009
- Clinical Trial: Phase 2: CCI-779 In Combination With Bevacizumab In Stage III OrNational Center For Research Resources2008–2009
- Multi-Epitope Melanoma Vaccines For CD4 And CD8 T-CellsNational Cancer Institute2005–2009
- Clinical Trial: Effects Of Local GM-CSF In-Adjuvant On Dendritic Cells In MelanoNational Center For Research Resources2008
- Targeted Molecular Therapeutics For Melanoma: CCI-779 And BevacizumabNational Cancer Institute2007–2008
- Evaluation Of Cyclophosphamide With Peptide Vaccines In Participants W/MelanomaNational Center For Research Resources2006–2008
- Leukapheresis Collection Of Wbc?S From Normals And Participants With CancerNational Center For Research Resources2007
- A Phase II Trial Of Vaccination With Peptides For Patients With MelanomaNational Center For Research Resources2006–2007
- Transdermal Adjuvant Administration Of Peptide-Based Vaccine, High-Risk MelanomaNational Center For Research Resources2005–2007
- Synthetic Helper Peptide Vaccines For Patients With Stage IV MelanomaNational Center For Research Resources2004–2007
- Efficacy Of A Melanoma Peptide Vaccine In Patients With Advanced MelanomaNational Center For Research Resources2005–2006
- Effects Of Local GM-CSF In-Adjuvant On Dendritic Cells In Melanoma PatientsNational Center For Research Resources2005–2006
- Effect Of GM-CSF And Vaccine Site Number On Immunization With Melanoma PeptidesNational Center For Research Resources2004–2006
- Peptide Vaccine For Patients With Advanced MelanomaNational Center For Research Resources2004–2005
- Immunogenicity Of Vaccination With Multiple Synthetic Melanoma PeptidesNational Center For Research Resources2004
- Efficacy Melanoma Peptide Vaccine For Advanced MelanomaNational Center For Research Resources2004
- Vaccines With MHC Class Ii-Restricted Melanoma PeptidesNational Cancer Institute2003–2004
- Multi-Epitope Melanoma Peptide Vaccination With GM-CSFNational Cancer Institute2003–2004
- Vaccination W/ Melanoma Peptides On Dendritic Cells Or W/ Gmcsf In AdjuvantNational Center For Research Resources1999–2002
- Pulsed Dendritic Cells For Induction Of Antitumor Immunity In Melanoma PatientsNational Center For Research Resources1998–2002
- Core--Tissue Procurement FacilityNational Cancer Institute1995–2002
- Autologous Melanoma Cell Vaccine With Gmcsf And IL2National Cancer Institute2000–2001
- Peptide Based Vaccines For Stage IV MelanomaNational Cancer Institute1998–2000
- HLA-A2 Associated Peptide Epitopes For CTL On MelanomaNational Cancer Institute1997–1999
- HLA-A2 Associated Peptide Epitopes For CTL On MelanomaNational Cancer Institute1992–1996
Professional Memberships
- Member
- Member
Hospital Affiliations
- University of Virginia Medical CenterCharlottesville, Virginia
- Emily Couric Clinical Cancer CenterCharlottesville, Virginia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: